Clinical trial
A Randomized, Double-blind, Placebo-controlled and Parallel Group Adaptive Phase 2b/3 Trial to Evaluate the Efficacy and Safety of TNM001 Injection for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants Under One Year of Age
NCT06083623 is registered in ClinicalTrials.gov with Zhuhai Trinomab Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled and Parallel Group Adaptive Phase 2b/3 Trial to Evaluate the Efficacy and Safety of TNM001 Injection for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants Under One Year of Age
- Lead sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- September 11, 2023
- Completion date
- November 5, 2025
- Enrollment
- 2,282 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.